

## PAPER

View Article Online  
View Journal | View Issue



Cite this: *Org. Biomol. Chem.*, 2023, **21**, 4144

Received 11th April 2023,

Accepted 20th April 2023

DOI: 10.1039/d3ob00563a

rsc.li/obc

# An expedient copper-catalysed asymmetric synthesis of $\gamma$ -lactones and $\gamma$ -lactams. Application to the synthesis of lucidulactone A†

O. Stephen Ojo, David L. Hughes and Christopher J. Richards \*

The parent Josiphos ligand gave excellent ee values (95–99%) and good yields (60–97%) in the copper-catalysed asymmetric conjugate reduction of  $\beta$ -aryl  $\alpha,\beta$ -unsaturated lactones and lactams with PMHS. The substrates were obtained from stereospecific copper-catalysed addition of arylboronic acids to alkynoates followed by deprotection and cyclisation. The acyclic lactam precursors also underwent reduction with good ee values (83–85%) and yields (79–95%). Application of this asymmetric reduction methodology included the synthesis of natural product lucidulactone A.


## Introduction

The construction of chiral  $\beta$ -substituted lactones and lactams has garnered considerable attention because of their ubiquitous existence as core structures in numerous biologically active natural products and clinical therapeutics.<sup>1</sup> For example, a chiral  $\gamma$ -butyrolactone is present in natural products lucidulactone A **1**<sup>2a</sup> and (3*R*)-A-factor **2**.<sup>2b</sup> Chiral  $\gamma$ -lactams are found in important pharmaceuticals such as rolipram **3**, an antidepressant drug (Fig. 1a). Also,  $\beta$ -GABA derivatives such as baclofen **4**, a muscle relaxant, can be accessed *via* hydrolysis of the corresponding chiral lactams (Fig. 1b).<sup>3a–c</sup> Consequently, the development of new methods for the synthesis of chiral  $\beta$ -substituted lactones and lactams, particularly in a stereocontrolled fashion, is of significant importance.

Two methods for the enantioselective synthesis of chiral lactams and lactones are transition metal catalysed and involve either: (i) conjugate addition of an organometallic derived nucleophile to an  $\alpha,\beta$ -unsaturated lactone or lactam precursor,<sup>4</sup> or (ii) reduction of an unsaturated  $\beta$ -substituted precursor. Although molecular hydrogen may be employed as the reducing agent,<sup>5</sup> a key development was the use of a copper catalyst incorporating the *P,P*-bidentate ligand *p*-tol-BINAP, and employing polymethylhydrosiloxane (PMHS) as the stoichiometric reductant (Scheme 1).<sup>6</sup> This biaryl ligand, which has also been applied to the corresponding reduction of

$\alpha,\beta$ -unsaturated esters<sup>7</sup> and enones,<sup>8</sup> has been superseded to some extent by other biaryl bisphosphines,<sup>9</sup> of which the most notable are the SEGPHOS ligands.<sup>10</sup> However, the specific application of the latter to the reduction of  $\beta$ -substituted unsaturated lactones is very limited.<sup>11</sup> The only other ligand type to give high product ee values in copper-catalysed conjugate reduction reactions are the ferrocene-based Josiphos ligands as applied to acyclic substrates including enones,<sup>12</sup> nitroalkenes<sup>13</sup> and unsaturated nitriles.<sup>14,15</sup>

In this Paper we report the highly enantioselective synthesis of  $\beta$ -substituted  $\gamma$ -lactones and lactams by copper-catalysed conjugate reduction employing a readily available Josiphos ligand. Coupled with the accessible synthesis of the unsaturated lactone and lactam precursors by copper-catalysed alkynoate-addition/cyclisation, the overall methodology provides rapid access to the title compounds in high ee.




**Fig. 1** Natural products and pharmaceutically relevant chiral  $\gamma$ -lactones and  $\gamma$ -lactams.

School of Chemistry, University of East Anglia, Norwich, NR4 7TJ, UK.

E-mail: Chris.Richards@uea.ac.uk

†Electronic supplementary information (ESI) available: Experimental detail, copies of the <sup>1</sup>H and <sup>13</sup>C spectra, HPLC traces and details of the X-ray crystal structure determinations. CCDC 2121166 and 2121167. For ESI and crystallographic data in CIF or other electronic format see DOI: <https://doi.org/10.1039/d3ob00563a>







**Scheme 1** Existing methods for the asymmetric synthesis of  $\beta$ -substituted  $\gamma$ -lactones and lactams by copper-catalysed asymmetric reduction.<sup>6</sup>

## Results and discussion

Previous methods for the synthesis of  $\beta$ -substituted butenolides include the use of ring-closing metathesis<sup>16</sup> and glyoxylic




**Scheme 2** Four-step synthesis of  $\beta$ -aryl  $\alpha,\beta$ -unsaturated lactones **9a-e**.



**Scheme 3** Five-step synthesis of  $\beta$ -aryl and  $\beta$ -alkyl  $\alpha,\beta$ -unsaturated lactams **15a-d**.

acid condensation followed by reduction.<sup>17</sup> For the generation of  $\beta$ -aryl derivatives we were attracted to the simplicity of copper-catalysed conjugate addition of arylboronic acids to appropriately functionalised alkynoates, followed by cyclisation,<sup>18</sup> and the potential to extend this methodology to give the corresponding lactams. Commencing with propargyl alcohol **5**, TBS-protection gave **6**, followed by treatment with *n*-BuLi and ethyl chloroformate to furnish alkynoate **7** (Scheme 2). The copper-catalysed conjugate *syn*-addition of



**Scheme 4** Synthesis of  $\beta$ -aryl  $\alpha,\beta$ -unsaturated lactones **9f**.

**Table 1** Asymmetric conjugate reduction: ligand discovery and optimisation<sup>a</sup>

Entry	Cu source (mol%)	L (mol%)	Conv. (time)	Yield <sup>b</sup> (%)	ee <sup>c</sup> (%) (config.)
1	$\text{CuCl}_2$ (5)	<i>R,S_p</i> - <b>L1</b> (6)	<5% (16 h)	—	—
2	$\text{CuCl}_2$ (5)	<i>S,S_p</i> - <b>L2</b> (6)	100% (16 h)	21	81 ( <i>R</i> )
3	( <i>R,S_p</i> )- <b>L3-CuCl}_2</b> <sup>d</sup> (3)	—	100% (22 h)	59	96 ( <i>R</i> )
4	( <i>R,S_p</i> )- <b>L3-CuBr</b> <sup>e</sup> (3)	—	100% (12 h)	78	99 ( <i>R</i> )
5	( <i>R,S_p</i> )- <b>L3-CuBr</b> (2)	—	95% (24 h)	67	98 ( <i>R</i> )

<sup>a</sup> On a 0.285 mmol scale, THF/*t*-BuOH (10 : 1). <sup>b</sup> Isolated yields. <sup>c</sup> Determined by HPLC analysis. <sup>d</sup>  $\text{Cu}(\text{OAc})_2$  and  $\text{Cu}(\text{OTf})_2$  also performed well (93 and 94% ee respectively). <sup>e</sup>  $\text{CuCl}$  also performed well (96% ee).

aryl boronic acids produced  $\beta$ -aryl-alkenoates (*Z*)-**8a–e** exclusively,<sup>18a</sup> and to ensure good yields the functionalised boronic acids required typically the use of 30 mol% Cu(OAc)<sub>2</sub>. A stoichiometric quantity of Cu(OAc)<sub>2</sub> was required with 2-methoxyphenylboronic acid to achieve conversion within twelve hours. Finally, acid mediated TBS deprotection and cyclisation of (*Z*)-**8a–e** furnished **9a–e**, such that  $\beta$ -substituted  $\alpha,\beta$ -unsaturated lactones were generated in four steps from commercially available propargyl alcohol (62–81% overall yield).

Extension of this methodology to PMP-protected  $\beta$ -substituted  $\alpha,\beta$ -unsaturated lactams required alkynoate **13** generated from Boc protection and propargylation of **10**, followed by reaction with ethyl chloroformate (Scheme 3). Conjugate addition of aryl boronic acids were successful using 5–30 mol% of Cu(OAc)<sub>2</sub> to generate  $\beta$ -aryl alkenoates **14a–c** as exclusively the *Z* diastereoisomer. As for the generation of (*Z*)-**8a–e**, this is a consequence of stereospecific carbocupration of the alkyne followed by rapid protonolysis avoiding possible *Z/E* isomerisation.<sup>18a</sup> Subsequent acid-promoted Boc deprotection and cyclisation gave lactams **15a–c** in five steps from *p*-anisidine (*ca.* 30% overall yield). Addition to **13** of an alkyl cuprate (Gilman reagent) generated from MeLi and CuI gave  $\beta$ -alkyl-

alkenoate (*Z*)-**14d** in good yield and as a single isomer,<sup>19</sup> with subsequent cyclisation providing  $\beta$ -alkyl lactam **15d**.

The conjugate addition of boronic acid **18** (obtained in three steps from commercially available **16**) to alkynoate **7** didn't generate the desired product. To solve this problem **18** was coupled successfully with **20** (obtained in one step from commercially available tetrone acid **19**) to produce **9f** (Scheme 4). The highly oxygenated phenolic moiety is present in many lignan natural products such as lucidulactone **A** <sup>2</sup> and descurinolide **A**.<sup>20</sup> The former was isolated from *Ganoderma lucidum*, a medicinal mushroom associated with various health benefits.

As the exploration of substrates of type **9f** in transition-metal catalysed asymmetric reactions are rare, the initial objective was the enantioselective reduction of this substrate as a key step in the synthesis of **1**. For this we chose to explore the use of ferrocene ligands as many are known with different chelating functional groups,<sup>21</sup> and within several ligand classes it is possible to vary readily substituents and stereochemistry for the purpose of ee optimisation (Table 1).<sup>22</sup>

In our initial ligand screen P,O ligand **L1** performed poorly (entry 1), whereas P,N ligand **L2** produced encouraging

**Table 2** Substrate scope for asymmetric conjugate reduction catalysed by (*R,S*<sub>p</sub>)-**L3**-CuBr

Entry <sup>a</sup>	Substrate	Product <sup>b,c</sup>	Entry <sup>a</sup>	Substrate	Product <sup>b,c</sup>	Entry <sup>a</sup>	Substrate	Product <sup>b,c</sup>
<b><math>\gamma</math>-Lactones</b>			<b><math>\gamma</math>-Lactams</b>			<b>Acyclic <math>\gamma</math>-lactam precursors</b>		
1		( <i>R</i> )- <b>21a</b> 97% yield 99% ee	6 <sup>d</sup>		( <i>R</i> )- <b>21f</b> 78% yield 99% ee	10		( <i>S</i> )- <b>22d</b> 94% yield 98% ee
2		( <i>R</i> )- <b>21b</b> 71% yield 98% ee						
3		( <i>R</i> )- <b>21c</b> 68% yield 97% ee	7		( <i>R</i> )- <b>22a</b> 95% yield 96% ee	11		( <i>R</i> )- <b>23a</b> 88% yield 83% ee
4		( <i>R</i> )- <b>21d</b> 95% yield 98% ee	8		( <i>R</i> )- <b>22b</b> 91% yield 97% ee	12		( <i>R</i> )- <b>23b</b> 79% yield 83% ee
5		( <i>R</i> )- <b>21e</b> 95% yield 99% ee	9		( <i>R</i> )- <b>22c</b> 86% yield 95% ee	13		( <i>R</i> )- <b>23c</b> 95% yield 85% ee


<sup>a</sup> The reactions were carried out on a 0.312 mmol scale using 3 mol% (*R,S*<sub>p</sub>)-**L3**-CuBr, PMHS (3 eq.), NaOt-Bu (2 eq.) in THF/*t*-BuOH (10 : 1), room temperature, 12 h. <sup>b</sup> Isolated yields. <sup>c</sup> Enantiomeric excess determined by chiral HPLC analysis. <sup>d</sup> (*S*)-**21f** was obtained in 78% yield and 99% ee using (*S*,*R*<sub>p</sub>)-**L3**-CuBr.



enantioselectivity (entry 2). Higher enantioselectivity was obtained with the P,P ligand **L3**, the parent Josiphos ligand,<sup>23</sup> as a preformed complex with CuCl<sub>2</sub> (entry 3). Switching to the CuBr complex gave lactone **6f** in good yield and with essentially complete control of enantioselectivity (entry 4) such that further ligand optimization was not needed. Using less than 3 mol% of this complex led to a longer reaction time and lower yield (entry 5).

Table 2 shows the substrate scope of this study, which was also extended to acyclic substrates (*Z*)-**14a–c**. The asymmetric conjugate reduction of **9a–9e** by (*R*,*S*<sub>p</sub>)-Josiphos complex **L3**-CuBr produced (*R*)-**21a–21e** with excellent enantioselectivities (≥97% ee; entries 1–5). Based on these results, this work proved to be a convenient method for generating β-aryl lactones. Both the (*R*) and (*S*) enantiomers of **21f** were generated in 99% ee using (*R*,*S*<sub>p</sub>)-**L3**-CuBr and (*S*,*R*<sub>p</sub>)-**L3**-CuBr, respectively (entry 6). The absolute configuration of (*R*)-**21d** and (*R*)-**21f** were confirmed by X-ray crystallography.<sup>24</sup> The absolute configuration of (*R*)-**21a–c** and (*R*)-**21e** were confirmed by optical rotation and comparison to the literature data.<sup>25</sup> Aryl and methyl β-substituted chiral γ-lactams **22a–d** were also generated with excellent enantioselectivities (≥95%; entries 7–10), and the absolute configuration of **22a**<sup>4</sup> and **22d**<sup>26</sup> were confirmed by optical rotation determination and comparison to the literature data.

Acyclic products **23a–c** were obtained in 83–85% ee (entries 11–13).<sup>27</sup> The absolute configuration of **23c** was determined as *R* following cyclisation to (*R*)-**22c**. Subsequent treatment with ceric ammonium nitrate generated (*R*)-**24c**,<sup>28</sup> which was converted to baclofen **4** in a previous study (Scheme 5a).<sup>3b</sup> Likewise, **23a** (78% ee), obtained from a larger scale reduction



Scheme 6 Synthesis of lucidulactone A.

reaction (1.71 g of (*Z*)-**14a** – 1.8 mol% catalyst loading), was cyclised to (*R*)-**22a**. Removal of the PMP group produced (*R*)-**24a** that was converted previously to high value chiral pyrrolidine (*R*)-**25** (Scheme 5b).<sup>3d</sup> Treatment of (*S*)-**22d** with ceric ammonium nitrate furnished known compound (*S*)-**24a**, which has been converted previously to a β-GABA derivative (*S*)-**26** (Scheme 5c).<sup>3a</sup> As the enantioselectivity of the reduction of the acyclic precursors to the unsaturated lactams is lower than that obtained with the unsaturated lactams themselves, reduction of the latter may of course be used to generate these products in higher ee.

Finally, the total synthesis of lucidulactone A **1** was completed in two steps from (*R*)-**21f** (Scheme 6). Treatment with LiHMDS followed by addition to the resulting enolate of oxaziridine (*R*)-**27** resulted in the highly diastereoselective formation of (*3S,4R*)-**28**.<sup>29</sup> Subsequent treatment with TBAF generated (*3S,4R*)-**1** in 71% over two steps. The specific rotation and NMR data obtained agree with the isolated sample data (see ESI†).<sup>2a</sup>

## Conclusions


In conclusion, the parent Josiphos ligand (**L3**) in combination with copper bromide gives a catalyst for the highly enantioselective reduction of β-aryl substituted α,β-unsaturated γ-lactones and γ-lactams using PMHS as the hydride source. Coupled with the generation of these reduction substrates by copper-catalysed stereospecific β-arylation of alkynoates, followed by cyclisation, this provides overall a simple and accessible methodology for the single enantiomer synthesis of the title compounds.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

The Leverhulme Trust (RPG-2018-270) (O. S. O.) is thanked for financial support.



Scheme 5 Formal synthesis of β-GABA derivatives and a chiral pyrrolidine.



## References

- (a) B. Mao, M. Fañanás-Mastral and B. L. Feringa, Catalytic Asymmetric Synthesis of Butenolides and Butyrolactones, *Chem. Rev.*, 2017, **117**, 10502–10566; (b) C. You, S. Li, X. Li, H. Lv and X. Zhang, Enantioselective Rh-Catalyzed Anti-Markovnikov Hydroformylation of 1,1-Disubstituted Allylic Alcohols and Amines: An Efficient Route to Chiral Lactones and Lactams, *ACS Catal.*, 2019, **9**, 8529–8533; (c) J. Sietmann, M. Ong, C. Mück-Lichtenfeld, C. Daniliuc and J. M. Wahl, Desymmetrization of Prochiral Cyclobutanones via Nitrogen Insertion: A Concise Route to Chiral  $\gamma$ -Lactams, *Angew. Chem., Int. Ed.*, 2021, **60**, 9719–9723.
- (a) X.-F. Wang, Y.-M. Yan, X.-L. Wang, X.-J. Ma, X.-Y. Fu and Y.-X. Cheng, Two new compounds from *Ganoderma lucidum*, *J. Asian Nat. Prod. Res.*, 2015, **17**, 329–332; (b) K. Mori, Revision of the Absolute Configuration of A-Factor, *Tetrahedron*, 1983, **39**, 3107–3109.
- (a) V. Rodríguez, M. Sánchez, L. Quintero and F. Sartillo-Piscil, The 5-*exo-trig* radical cyclization reaction under reductive and oxidative conditions in the synthesis of optically pure GABA derivatives, *Tetrahedron*, 2004, **60**, 10809–10815; (b) I. J. Montoya-Balbás, B. Valentín-Guevara, E. López-Mendoza, I. Linzaga-Elizalde, M. Ordoñez and P. Román-Bravo, Efficient Synthesis of  $\beta$ -Aryl- $\gamma$ -lactams and Their Resolution with (*S*)-Naproxen: Preparation of (*R*)- and (*S*)-Baclofen, *Molecules*, 2015, **20**, 22028–22043; (c) K. Biswas, R. Gholap, P. Srinivas, S. Kanyal and K. Das Sarma,  $\beta$ -substituted  $\gamma$ -butyrolactams from mucochloric acid: synthesis of ( $\pm$ )-baclofen and other  $\gamma$ -aminobutyric acids and useful building blocks, *RSC Adv.*, 2014, **4**, 2538–2545; (d) X. Li, C. You, Y. Yang, Y. Yang, P. Li, G. Gu, L. W. Chung, H. Lv and X. Zhang, Rhodium-catalyzed asymmetric hydrogenation of  $\beta$ -cyanocinnamic esters with the assistance of a single hydrogen bond in a precise position, *Chem. Sci.*, 2018, **9**, 1919–1924.
- C. Shao, H.-J. Yu, N.-Y. Wu, P. Tian, R. Wang, C.-G. Feng and G.-Q. Lin, Asymmetric Synthesis of  $\beta$ -Substituted  $\gamma$ -Lactams via Rhodium/Diene-Catalyzed 1,4-Additions: Application to the Synthesis of (*R*)-Baclofen and (*R*)-Rolipram, *Org. Lett.*, 2011, **13**, 788–791.
- (a) J. J. Verendel, J.-Q. Li, X. Quan, B. Peters, T. Zhou, O. R. Gautun, T. Govender and P. G. Andersson, Chiral Hetero- and Carbocyclic Compounds from the Asymmetric Hydrogenation of Cyclic Alkenes, *Chem. – Eur. J.*, 2012, **18**, 6507–6513; (b) Q. Lang, G. Gu, Y. Cheng, Q. Yin and X. Zhang, Highly Enantioselective Synthesis of Chiral  $\gamma$ -Lactams by Rh-Catalyzed Asymmetric Hydrogenation, *ACS Catal.*, 2018, **8**, 4824–4828.
- (a) G. Hughes, M. Kimura and S. L. Buchwald, Catalytic Enantioselective Conjugate Reduction of Lactones and Lactams, *J. Am. Chem. Soc.*, 2003, **125**, 11253–11258; (b) G. L. Larson and R. J. Liberatore, Organosilanes in Metal-Catalyzed, Enantioselective Reductions, *Org. Process Res. Dev.*, 2021, **25**, 1719–1787.
- D. H. Appella, Y. Moritani, R. Shintani, E. M. Ferreira and S. L. Buchwald, Asymmetric Conjugate Reduction of  $\alpha,\beta$ -Unsaturated Esters Using a Chiral Phosphine-Copper Catalyst, *J. Am. Chem. Soc.*, 1999, **121**, 9473–9474.
- (a) Y. Moritani, D. H. Appella, V. Jurkauskas and S. L. Buchwald, Synthesis of  $\beta$ -Alkyl Cyclopentanones in High Enantiomeric Excess via Copper-Catalyzed Asymmetric Conjugate Reduction, *J. Am. Chem. Soc.*, 2000, **122**, 6797–6798; (b) V. Jurkauskas and S. L. Buchwald, Dynamic Kinetic Resolution via Asymmetric Conjugate Reduction: Enantio- and Diastereoselective Synthesis of 2,4-Dialkyl Cyclopentanones, *J. Am. Chem. Soc.*, 2002, **124**, 2892–2893.
- M. P. Rainka, J. E. Milne and S. L. Buchwald, Dynamic Kinetic Resolution of  $\alpha,\beta$ -Unsaturated Lactones through Asymmetric Copper-Catalyzed Conjugate Reduction: Application to the Total Synthesis of Eupomatilone, *Angew. Chem., Int. Ed.*, 2005, **44**, 6177–6180.
- (a) B. H. Lipshutz, J. M. Servesko, T. B. Petersen, P. P. Papa and A. A. Lover, Asymmetric 1,4-Reductions of Hindered  $\beta$ -Substituted Cycloalkenones Using Catalytic SEGPHOS-Ligated CuH, *Org. Lett.*, 2004, **6**, 1273–1275; (b) B. H. Lipshutz, J. M. Servesko and B. R. Taft, Asymmetric 1,4-Hydrosilylations of  $\alpha,\beta$ -Unsaturated Esters, *J. Am. Chem. Soc.*, 2004, **126**, 8352–8353.
- Using DTBM-SEGPHOS with  $(\text{Ph}_3\text{P})\text{CuH}$  and PMHS, 4-phenylfuran-2(5*H*)-one is reduced in 99% ee.<sup>10b</sup> See also: B. H. Lipshutz, B. A. Frieman, J. B. Unger and D. M. Nihan, Thermally Accelerated Asymmetric Hydrosilylations Using Ligated Copper Hydride, *Can. J. Chem.*, 2005, **83**, 606–614.
- B. H. Lipshutz and J. M. Servesko, CuH-Catalyzed Asymmetric Conjugate Reductions of Acyclic Enones, *Angew. Chem., Int. Ed.*, 2003, **42**, 4789–4792.
- C. Czekelius and E. M. Carreira, Catalytic Enantioselective Conjugate Reduction of  $\beta,\beta$ -Disubstituted Nitroalkenes, *Angew. Chem., Int. Ed.*, 2003, **42**, 4793–4795.
- D. Lee, D. Kim and J. Yun, Highly Enantioselective Conjugate Reduction of  $\beta,\beta$ -Disubstituted  $\sigma,\beta$ -Unsaturated Nitriles, *Angew. Chem., Int. Ed.*, 2006, **45**, 2785–2787.
- With some of these substrates use of DTBM-SEGPHOS gives poor results highlighting the significance of ligand choice as a function of the substrate. See: B. H. Lipshutz, Rediscovering Organocopper Chemistry Through Copper Hydride. It's All About the Ligand, *Synlett*, 2009, 509–524.
- (a) A. K. Chatterjee, J. P. Morgan, M. Scholl and R. H. Grubbs, Synthesis of Functionalized Olefins by Cross and Ring-Closing Metatheses, *J. Am. Chem. Soc.*, 2000, **122**, 3783–3784; (b) A. Fürstner, O. R. Thiel, L. Ackermann, H.-J. Schanz and S. P. Nolan, Ruthenium Carbene Complexes with *N,N*-Bis(mesityl)imidazol-2-ylidene Ligands: RCM Catalysts of Extended Scope, *J. Org. Chem.*, 2000, **65**, 2204–2207.
- J. J. Bourguignon and C. G. Wermuth, Synthesis of  $\beta$ -Substituted,  $\gamma$ -Functionalized Butanolides and Butenolides and Succinaldehydic Acids from Glyoxylic Acid, *J. Org. Chem.*, 1981, **46**, 4889–4894.





- 18 (a) Y. Yamamoto, N. Kira and Y. Harada, Cu-catalyzed stereoselective conjugate addition of arylboronic acids to alkynoates, *Chem. Commun.*, 2008, 2010–2012; (b) Y. Yamamoto and N. Kirai, Synthesis of 4-Aryl-Substituted Butenolides and Pentenolides by Copper-Catalysed Hydroarylation, *Heterocycles*, 2010, **80**, 269–279.
- 19 E. J. Corey and J. A. Katzenellenbogen, A New Stereospecific Synthesis of Trisubstituted and Tetrasubstituted Olefins. The Conjugate Addition of Dialkylcopper-Lithium Reagents to  $\alpha,\beta$ -Acetylenic Esters, *J. Am. Chem. Soc.*, 1969, **91**, 1851–1852.
- 20 O. S. Ojo, B. Nardone, S. F. Musolino, A. R. Neal, L. Wilson, T. Lebl, A. M. Z. Slawin, D. B. Cordes, J. E. Taylor, J. H. Naismith, A. D. Smith and N. J. Westwood, Synthesis of the natural product descrainolide and cyclic peptides from lignin-derived aromatics, *Org. Biomol. Chem.*, 2018, **16**, 266–273.
- 21 R. G. Arrayás, J. Adrio, J. Carlos and J. C. Carretero, Recent Applications of Chiral Ferrocene Ligands in Asymmetric Catalysis, *Angew. Chem., Int. Ed.*, 2006, **45**, 7674–7715.
- 22 (a) R. A. Arthurs, D. L. Hughes and C. J. Richards, Stereoselective Synthesis of All Possible Phosferox Ligand Diastereoisomers Displaying Three Elements of Chirality: Stereochemical Optimization for Asymmetric Catalysis, *J. Org. Chem.*, 2020, **85**, 4838–4847; (b) R. A. Arthurs, A. C. Dean, D. L. Hughes and C. J. Richards, Copper(I) Complexes of *P*-Stereogenic Josiphos and Related Ligands, *Eur. J. Org. Chem.*, 2021, 2719–2725.
- 23 A. Togni, C. Breutel, A. Schnyder, F. Spindler, H. Landert and A. Tijani, A Novel Easily Accessible Chiral Ferrocenyldiphosphine for Highly Enantioselective Hydrogenation, Allylic Alkylation, and Hydroboration Reactions, *J. Am. Chem. Soc.*, 1994, **116**, 4062–4066.
- 24 CCDC 2121166 and 2121167 contains the supplementary crystallographic data for this paper.†
- 25 (a) A. V. Malkov, F. Friscourt, M. Bell, M. E. Swarbrick and P. Kočovský, Enantioselective Baeyer-Villiger Oxidation Catalyzed by Palladium(II) Complexes with Chiral *P,N*-Ligands, *J. Org. Chem.*, 2008, **73**, 3996–4003; (b) C. O. Oliveira, R. A. Angnes and C. R. D. Correia, Intermolecular Enantioselective Heck-Matsuda Arylations of Acyclic Olefins: Application to the Synthesis of  $\beta$ -Aryl- $\gamma$ -Lactones and  $\beta$ -Aryl Aldehydes, *J. Org. Chem.*, 2013, **78**, 4373–4385.
- 26 Determined following deprotection to (*S*)-**24d** and comparison to literature data: J. Barluenga, F. Aznar, C. Ribas and C. Valdés, Cycloaddition Reactions of Chiral 2-Amino-1,3-butadienes with Nitroalkenes: Synthesis of Enantiomerically Pure 4-Nitrocyclohexanones, *J. Org. Chem.*, 1997, **62**, 6746–6753.
- 27 It is anticipated that the  $\gamma$ -lactone precursors (*Z*)-**8a–e** will result in a similar level of enantioselectivity under these conditions.
- 28 Deprotection of the PMP group with ceric ammonium nitrate (CAN) is known to proceed without compromising adjacent stereogenic centres. See, for example: (a) J. J. Fleming and J. Du Bois, A Synthesis of (+)-Saxitoxin, *J. Am. Chem. Soc.*, 2006, **128**, 3926–3927; (b) D. Y. Park, K.-H. Kim and C.-H. Cheon, Enantioselective Synthesis of  $\beta$ -Aminotetralins via Chiral Phosphoric Acid-catalyzed Reductive Amination of  $\beta$ -Tetralones, *Adv. Synth. Catal.*, 2018, **360**, 462–467.
- 29 F. A. Davis, A. C. Sheppard, B.-C. Chen and M. S. Haque, Chemistry of Oxaziridines. 14. Asymmetric oxidation of ketone enolates using enantiomerically pure (camphorylsulfonyl)oxaziridine, *J. Am. Chem. Soc.*, 1990, **112**, 6679–6690.

